Real world evidence in asthma: what to expect beyond randomised controlled trials?
- PMID: 38991724
- DOI: 10.1183/13993003.00716-2024
Real world evidence in asthma: what to expect beyond randomised controlled trials?
Conflict of interest statement
Conflict of interest: T. Soumagne reports personal fees from GSK, Menarini, AstraZeneca, Sanofi-Aventis and ALK, outside the submitted work. B. Degano has no potential conflicts of interest to declare.
Comment on
-
Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme.Eur Respir J. 2024 Jul 11;64(1):2301521. doi: 10.1183/13993003.01521-2023. Print 2024 Jul. Eur Respir J. 2024. PMID: 38575162 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical